# A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

> **NCT04603040** · PHASE2 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04603040
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-28
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603040, "A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04603040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*